References
- Handbook of stereoisomers: Drugs in psychopharmacology, D F Smith. CRC Press, Boca Raton, Fl. 1984
- Smith D F. Stereopsychopharmacology: Past, present and future. Prog Neuropsychopharmacol Biol Psychiatry 1984; 8: 327–50
- Bøgesø K P, Hyttel J, Christensen A V, Arnt J. Chirality as determinant for neuroleptic or antidepressant action of drugs. Innovative approaches in drug research, A F Harms. Elsevier Science Publ. B V, Amsterdam 1986; 371–92
- Portoghese P S. Relationships between stereostructure and pharmacological activities. Annu Rev Pharmacol 1970; 10: 51–76
- Gilbert S F, Greenberg J P. Intellectual traditions in the life sciences. II. Stereocomplementarity. Perspect Biol Med 1984; 28: 18–34
- Smith D F. The stereoselectivity of serotonin uptake in brain tissue and blood platelets: The topography of the serotonin uptake area. Neurosci Biobehav Rev 1986; 10: 37–46
- Cavallito C J. Some trends in the development of structure-activity relationships (SAR) and theory of receptors. Structure-activity relationships. Vol. 1. International encyclopedia of pharmacology and therapeutics. Section 5, C J Cavallito. Pergamon Press, Oxford 1973; 1–35
- Humblet C, Marshall G R. Three-dimensional computer modeling as an aid to drug design. Drug Development Res 1981; 1: 409–34
- Horn A S, Snyder S H. Chlorpromazine and dopamine: Conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs. Proc Nat Acad Sci USA 1971; 68: 2325–8
- Bartholow E J, Eiden L E, Ruth J A, Grunewald G L, Siebert J, Rutledge C O. Conformationally defined adrenergic agents. II. The effect of endo-and exo-2-aminobenzobicyclo - 2.2.2. octene, conformationally defined amphetamine analogs, on the uptake and release of central catecholamines. J. Pharmacol Exp Ther 1977, 202–532–43.
- Bøgesø K P. Neuroleptic activity and dopamine-uptake inhibition in l-piperazino-3-phenylindans. J Med Chem 1983; 26: 935–47
- Jenner P, Testa B. The influence of stereochemical factors on drug disposition. Drug Metab Rev 1973; 2: 117–84
- Bird P H, Bruderlein F T, Humber L G. Crystallographic studies on neuroleptics of the benzocycloheptapyridoisoquinoline series. The crystal structure of butaclamol hydrobromide and the absolute configuration and crystal structure of dexclamol hydrobromide. Can J Chem 1976; 54: 2715–22
- Heilizer F. A critical review of some published experiments with chlorpromazine in schizophrenic, neurotic, and normal humans. J Chron Dis 1960; 11: 102–48
- Seeman P. Brain dopamine receptors. Pharmacol Rev 1981; 32: 229–313
- Carlsson A. Mechanism of action of neuroleptic drugs. Psychopharmacology: A generation of progress, M A Lipton, A DiMascio, K F Killam. Raven Press, New York 1978; 1057–70
- Hyttel J, Arnt J, Bøgesø K P. Antipsychotic drugs: Configurational stereoisomers. CRC Handbook of stereoisomers: Drugs in psychopharmacology, D F Smith. CRC Press, Boca Raton, FI. 1984; 143–214
- Johnstone E C, Crow T J, Firth C D, Carney M WP, Price J S. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978; 1: 848–51
- Barnett A. Review on dopamine receptors. Drugs of the Future 1986; 11: 49–56
- Cohen N C. Drug design in three dimensions. Advances in drug research, B Testa. Academic Press, London 1985; Vol 14: 41–145
- Humber L G, Bruderlein F T, Philipp A H, Gitz M, Voith K. Mapping the dopamine receptor. 1. Features derived from modifications in ring E of the neuroleptic butaclamol. J Med Chem 1979; 22: 761–7
- Olson G L, Cheung H-O, Morgan K D, Blount J F, Todaro L, Berger L, Davidson A B, Boff E. A dopamine receptor model and its application in the design of a new class of rigid pyrrolo 2,3-g isoquinoline antipsychotics. J Med Chem 1981; 24: 1026–34